SRNE vs. EVAX, APTO, PMCB, SNTI, TVGN, IKT, ONVO, COEP, BCDA, and GENE
Should you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include Evaxion Biotech A/S (EVAX), Aptose Biosciences (APTO), PharmaCyte Biotech (PMCB), Senti Biosciences (SNTI), Tevogen Bio (TVGN), Inhibikase Therapeutics (IKT), Organovo (ONVO), Coeptis Therapeutics (COEP), BioCardia (BCDA), and Genetic Technologies (GENE). These companies are all part of the "biological products, except diagnostic" industry.
Evaxion Biotech A/S (NASDAQ:EVAX) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.
Sorrento Therapeutics received 593 more outperform votes than Evaxion Biotech A/S when rated by MarketBeat users. Likewise, 70.77% of users gave Sorrento Therapeutics an outperform vote while only 56.67% of users gave Evaxion Biotech A/S an outperform vote.
Evaxion Biotech A/S has higher earnings, but lower revenue than Sorrento Therapeutics.
11.0% of Evaxion Biotech A/S shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 41.6% of Evaxion Biotech A/S shares are owned by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Evaxion Biotech A/S's return on equity of 0.00% beat Sorrento Therapeutics' return on equity.
Evaxion Biotech A/S has a beta of -0.22, meaning that its share price is 122% less volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500.
Evaxion Biotech A/S presently has a consensus price target of $11.00, indicating a potential upside of 199.73%. Given Sorrento Therapeutics' higher possible upside, equities analysts plainly believe Evaxion Biotech A/S is more favorable than Sorrento Therapeutics.
In the previous week, Evaxion Biotech A/S had 3 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 5 mentions for Evaxion Biotech A/S and 2 mentions for Sorrento Therapeutics. Sorrento Therapeutics' average media sentiment score of 0.89 beat Evaxion Biotech A/S's score of 0.00 indicating that Evaxion Biotech A/S is being referred to more favorably in the media.
Summary
Evaxion Biotech A/S beats Sorrento Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Sorrento Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sorrento Therapeutics Competitors List
Related Companies and Tools
